Cat. No.: HY-13624

Epirubicin

(Synonyms: 4'-Epidoxorubicin)

38 Cited Publications

Customer Review

Based on 38 publication(s) in Google Scholar

Epirubicin (4'-Epidoxorubicin), a semisynthetic L-arabino derivative of doxorubicin, has an antineoplastic agent by inhibiting Topoisomerase. Epirubicin inhibits DNA and RNA synthesis. Epirubicin is a Forkhead box protein p3 (Foxp3) inhibitor and inhibits regulatory T cell activity.

For research use only. We do not sell to patients.

Purity: 99.61%
CAS No.: 56420-45-2
Formula: C₂₇H₂₉NO₁₁
Molecular Weight:543.52

Storage:

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Epirubicin Chemical Structure

CAS No.: 56420-45-2

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (38)
Solvent & Solubility
- In Vitro
Protocol
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Epirubicin (4'-Epidoxorubicin), a semisynthetic L-arabino derivative of doxorubicin, has an antineoplastic agent by inhibiting Topoisomerase^[1]. Epirubicin inhibits DNA and RNA synthesis. Epirubicin is a Forkhead box protein p3 (Foxp3) inhibitor and inhibits regulatory T cell activity^[2].

IC₅₀ & Target^[1]

Topoisomerase

FOXP3

All DNA/RNA Synthesis Isoforms :

All Topoisomerase Isoforms :

All Antibiotic Isoforms :

All FOXP Isoforms :

FOXP3

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	IC₅₀	1.277 μM Compound: Epirubicin	Cytotoxicity against human A2780 cells assessed as cell viability measured after 48 hrs by MTT assay Cytotoxicity against human A2780 cells assessed as cell viability measured after 48 hrs by MTT assay	[PMID: 38964974]
A549	IC₅₀	0.63 μM Compound: Epirubicin	Cytotoxicity against human A549 cells assessed as decrease in cell viability after 72 hrs by MTS assay Cytotoxicity against human A549 cells assessed as decrease in cell viability after 72 hrs by MTS assay	[PMID: 27560695]
A549	IC₅₀	0.82 μM Compound: Epirubicin	Cytotoxicity against human A549 cells expressing wild type p53 assessed as reduction in cell viability preincubated for 48 hrs and measured after 4 hrs by MTT assay Cytotoxicity against human A549 cells expressing wild type p53 assessed as reduction in cell viability preincubated for 48 hrs and measured after 4 hrs by MTT assay	[PMID: 31761381]
A549	IC₅₀	0.88 mM Compound: Epirubicin	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 22940450]
A549	IC₅₀	1.32 μM Compound: EPI	Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation measured after 68 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation measured after 68 hrs by MTT assay	[PMID: 34852194]
A549	IC₅₀	9.6 μM Compound: Epirubicin	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 23287057]
Bcap37	IC₅₀	0.89 mM Compound: Epirubicin	Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay	[PMID: 22940450]
Bel-7402	IC₅₀	1.23 mM Compound: Epirubicin	Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay	[PMID: 22940450]
Caco-2	IC₅₀	0.41 mM Compound: Epirubicin	Cytotoxicity against human Caco2 cells after 72 hrs by MTT assay Cytotoxicity against human Caco2 cells after 72 hrs by MTT assay	[PMID: 22940450]
DU-145	IC₅₀	2.01 μM Compound: Epirubicin	Cytotoxicity against human DU145 cells expressing mutant type p53 assessed as reduction in cell viability preincubated for 48 hrs and measured after 4 hrs by MTT assay Cytotoxicity against human DU145 cells expressing mutant type p53 assessed as reduction in cell viability preincubated for 48 hrs and measured after 4 hrs by MTT assay	[PMID: 31761381]
DU-145	IC₅₀	4.01 mM Compound: Epirubicin	Cytotoxicity against human DU145 cells after 72 hrs by MTT assay Cytotoxicity against human DU145 cells after 72 hrs by MTT assay	[PMID: 22940450]
DU-145	IC₅₀	9.9 μM Compound: Epirubicin	Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay	[PMID: 23287057]
Fibroblast	IC₅₀	>20 μM Compound: Epirubicin	Antiproliferative activity against mouse fibroblasts after 48 hrs by MTT assay Antiproliferative activity against mouse fibroblasts after 48 hrs by MTT assay	[PMID: 23287057]
HCT-116	IC₅₀	0.37 μM Compound: EPI	Cytotoxicity in human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity in human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31251621]
HCT-116	IC₅₀	0.37 μM Compound: Epirubicin	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 28119026]
HCT-116	IC₅₀	0.4 μM Compound: Epirubicin	Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 29767975]
HCT-116	IC₅₀	0.57 mM Compound: Epirubicin	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 22940450]
HCT-116	IC₅₀	0.82 μM Compound: EPI	Cytotoxicity against human HCT116 cells after 6 days by MTT assay Cytotoxicity against human HCT116 cells after 6 days by MTT assay	[PMID: 22276679]
HEK-293T	IC₅₀	0.47 μM Compound: Epirubicin	Cytotoxicity against HEK293T cells assessed as decrease in cell viability after 72 hrs by MTS assay Cytotoxicity against HEK293T cells assessed as decrease in cell viability after 72 hrs by MTS assay	[PMID: 27560695]
HeLa	IC₅₀	0.42 μM Compound: Epirubicin	Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 72 hrs by MTS assay Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 72 hrs by MTS assay	[PMID: 27560695]
HeLa	IC₅₀	0.51 μg/mL Compound: EPI	Cytotoxicity against human HeLa cells after 6 days by MTT method Cytotoxicity against human HeLa cells after 6 days by MTT method	[PMID: 21545109]
Hep 3B2	IC₅₀	0.96 μM Compound: EPI	Cytotoxicity against human Hep3B cells after 6 days by MTT assay Cytotoxicity against human Hep3B cells after 6 days by MTT assay	[PMID: 22276679]
HepG2	IC₅₀	0.1 μM Compound: Epirubicin	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 29767975]
HepG2	IC₅₀	0.32 μM Compound: Epirubicin	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 28119026]
HepG2	IC₅₀	0.56 μg/mL Compound: EPI	Cytotoxicity against human HepG2 after 6 days by MTT method Cytotoxicity against human HepG2 after 6 days by MTT method	[PMID: 21545109]
HepG2	IC₅₀	0.96 μM Compound: Epirubicin	Cytotoxicity against human HepG2 cells incubated for 48 hrs by MTT assay Cytotoxicity against human HepG2 cells incubated for 48 hrs by MTT assay	[PMID: 34128674]
HepG2	IC₅₀	1.3 μM Compound: Epirubicin	Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 72 hrs by MTS assay Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 72 hrs by MTS assay	[PMID: 27560695]
HepG2	IC₅₀	1.65 μM Compound: EPI	Cytotoxicity against human HepG2 cells after 6 days by MTT assay Cytotoxicity against human HepG2 cells after 6 days by MTT assay	[PMID: 22276679]
HepG2	IC₅₀	2.23 mM Compound: Epirubicin	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 22940450]
HepG2	IC₅₀	4.6 μM Compound: Epirubicin	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 23287057]
HT-29	IC₅₀	3.36 μM Compound: EPI	Cytotoxicity against human HT-29 cells assessed as inhibition of cell proliferation measured after 68 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as inhibition of cell proliferation measured after 68 hrs by MTT assay	[PMID: 34852194]
Huh-7	IC₅₀	0.495 μM Compound: Epirubicin	Cytotoxicity against human Huh-7 cells assessed as cell viability measured after 48 hrs by MTT assay Cytotoxicity against human Huh-7 cells assessed as cell viability measured after 48 hrs by MTT assay	[PMID: 38964974]
Huh-7	IC₅₀	9.12 μM Compound: EPI	Cytotoxicity against human Huh-7 cells assessed as inhibition of cell proliferation measured after 68 hrs by MTT assay Cytotoxicity against human Huh-7 cells assessed as inhibition of cell proliferation measured after 68 hrs by MTT assay	[PMID: 34852194]
K562	IC₅₀	0.239 μM Compound: 2	Cytotoxicity against human K562 cells incubated for 2 hrs followed by compound washout and measured after 72 hrs by Celltiter-blue viability assay Cytotoxicity against human K562 cells incubated for 2 hrs followed by compound washout and measured after 72 hrs by Celltiter-blue viability assay	[PMID: 39088428]
K562	IC₅₀	0.429 μM Compound: 2	Cytotoxicity against human K562 cells overexpressing ABCG2 incubated for 2 hrs followed by compound washout and measured after 72 hrs by Celltiter-blue viability assay Cytotoxicity against human K562 cells overexpressing ABCG2 incubated for 2 hrs followed by compound washout and measured after 72 hrs by Celltiter-blue viability assay	[PMID: 39088428]
K562	IC₅₀	2.038 μM Compound: 2	Cytotoxicity against human K562 cells overexpressing ABCB1 incubated for 2 hrs followed by compound washout and measured after 72 hrs by Celltiter-blue viability assay Cytotoxicity against human K562 cells overexpressing ABCB1 incubated for 2 hrs followed by compound washout and measured after 72 hrs by Celltiter-blue viability assay	[PMID: 39088428]
L02	IC₅₀	1.74 mM Compound: Epirubicin	Cytotoxicity against human HL-7702 cells after 72 hrs by MTT assay Cytotoxicity against human HL-7702 cells after 72 hrs by MTT assay	[PMID: 22940450]
L02	IC₅₀	2.1 μM Compound: Epirubicin	Cytotoxicity against human HL-7702 cells expressing wild type p53 assessed as reduction in cell viability preincubated for 48 hrs and measured after 4 hrs by MTT assay Cytotoxicity against human HL-7702 cells expressing wild type p53 assessed as reduction in cell viability preincubated for 48 hrs and measured after 4 hrs by MTT assay	[PMID: 31761381]
MCF-10A	IC₅₀	0.1 μM Compound: Epirubicin	Cytotoxicity against human MCF10A cells after 48 hrs by MTT assay Cytotoxicity against human MCF10A cells after 48 hrs by MTT assay	[PMID: 29767975]
MCF-10A	IC₅₀	0.13 μM Compound: Epirubicin	Cytotoxicity against human MCF10A cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MCF10A cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 28119026]
MCF7	IC₅₀	0.55 μM Compound: Epirubicin	Cytotoxicity against human MCF7 cells incubated for 72 hrs by SRB assay Cytotoxicity against human MCF7 cells incubated for 72 hrs by SRB assay	[PMID: 33479665]
MCF7	IC₅₀	0.56 μg/mL Compound: EPI	Cytotoxicity against human MCF7 cells after 6 days by MTT method Cytotoxicity against human MCF7 cells after 6 days by MTT method	[PMID: 21545109]
MCF7	IC₅₀	0.71 μM Compound: Epirubicin	Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 72 hrs by MTS assay Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 72 hrs by MTS assay	[PMID: 27560695]
MCF7	IC₅₀	1.25 mM Compound: Epirubicin	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 22940450]
MCF7	IC₅₀	200 nmol equiv/L Compound: Epidoxorubicin	Compound was tested for its toxicity against human breast cancer cells(MCF-7) Compound was tested for its toxicity against human breast cancer cells(MCF-7)	[PMID: 9548820]
MCF7	IC₅₀	3.7 μM Compound: Epirubicin	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 23287057]
MDA-MB-231	IC₅₀	0.15 μM Compound: Epirubicin	Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs	[PMID: 33139111]
MDA-MB-231	IC₅₀	0.9 μM Compound: Epirubicin	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 29767975]
MDA-MB-231	IC₅₀	1.2 μM Compound: EPI	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 68 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 68 hrs by MTT assay	[PMID: 34852194]
MDA-MB-231	IC₅₀	5.6 μM Compound: EPI	Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31251621]
MDA-MB-231	IC₅₀	5.6 μM Compound: Epirubicin	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 23287057]
MDA-MB-435	IC₅₀	0.23 μM Compound: EPI	Cytotoxicity against human MDA-MB-435 cells assessed as inhibition of cell proliferation measured after 68 hrs by MTT assay Cytotoxicity against human MDA-MB-435 cells assessed as inhibition of cell proliferation measured after 68 hrs by MTT assay	[PMID: 34852194]
MDA-MB-435	IC₅₀	0.26 μM Compound: EPI	Cytotoxicity in human MDA-MB-435 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity in human MDA-MB-435 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31251621]
MDA-MB-435	IC₅₀	0.26 μM Compound: Epirubicin	Cytotoxicity against human MDA-MB-435 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-435 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 28119026]
MDA-MB-435	IC₅₀	0.33 μg/mL Compound: EPI	Cytotoxicity against human MDA-MB-435 after 6 days by MTT method Cytotoxicity against human MDA-MB-435 after 6 days by MTT method	[PMID: 21545109]
MDA-MB-435	IC₅₀	0.7 μM Compound: Epirubicin	Cytotoxicity against human MDA-MB-435 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-435 cells after 48 hrs by MTT assay	[PMID: 29767975]
MGC-803	IC₅₀	1.2 μM Compound: Epirubicin	Cytotoxicity against human MGC-803 cells expressing mutant type p53 assessed as reduction in cell viability preincubated for 48 hrs and measured after 4 hrs by MTT assay Cytotoxicity against human MGC-803 cells expressing mutant type p53 assessed as reduction in cell viability preincubated for 48 hrs and measured after 4 hrs by MTT assay	[PMID: 31761381]
MIA PaCa-2	IC₅₀	>100 μM Compound: 4; epi	Cytotoxicity against doxorubicin-sensitive human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 90 mins by crystal violet staining assay Cytotoxicity against doxorubicin-sensitive human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 90 mins by crystal violet staining assay	[PMID: 26881291]
MIA PaCa-2	IC₅₀	0.5 μM Compound: 4; epi	Synergistic cytotoxicity against doxorubicin-sensitive human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 90 mins in presence of formaldehyde by crystal violet staining assay Synergistic cytotoxicity against doxorubicin-sensitive human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 90 mins in presence of formaldehyde by crystal violet staining assay	[PMID: 26881291]
MKN-45	IC₅₀	0.66 mM Compound: Epirubicin	Cytotoxicity against human MKN45 cells after 72 hrs by MTT assay Cytotoxicity against human MKN45 cells after 72 hrs by MTT assay	[PMID: 22940450]
NCI/ADR-RES	IC₅₀	>10000 nmol equiv/L Compound: Epidoxorubicin	Compound was tested for its toxicity against doxorubicin resistant human breast cancer cells (MCF-7/ADR). Compound was tested for its toxicity against doxorubicin resistant human breast cancer cells (MCF-7/ADR).	[PMID: 9548820]
NCI/ADR-RES	IC₅₀	1.65 μM Compound: EPI	Cytotoxicity against human MCF7/ADR cells after 6 days by MTT assay Cytotoxicity against human MCF7/ADR cells after 6 days by MTT assay	[PMID: 22276679]
NCI/ADR-RES	IC₅₀	630 nM Compound: 4; epi	Cytotoxicity against doxorubicin-resistant human NCI/ADR-RES cells assessed as inhibition of cell growth incubated for 90 mins by crystal violet staining assay Cytotoxicity against doxorubicin-resistant human NCI/ADR-RES cells assessed as inhibition of cell growth incubated for 90 mins by crystal violet staining assay	[PMID: 26881291]
NCI-H157	IC₅₀	1.72 mM Compound: Epirubicin	Cytotoxicity against human NCI-H157 cells after 72 hrs by MTT assay Cytotoxicity against human NCI-H157 cells after 72 hrs by MTT assay	[PMID: 22940450]
NCI-H446	IC₅₀	2.35 mM Compound: Epirubicin	Cytotoxicity against human NCI-H446 cells after 72 hrs by MTT assay Cytotoxicity against human NCI-H446 cells after 72 hrs by MTT assay	[PMID: 22940450]
NCI-H460	IC₅₀	0.02 μM Compound: Epirubicin	Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay	[PMID: 29767975]
NCI-H460	IC₅₀	0.06 μM Compound: EPI	Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell proliferation measured after 68 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell proliferation measured after 68 hrs by MTT assay	[PMID: 34852194]
NCI-H460	IC₅₀	0.12 μM Compound: EPI	Cytotoxicity in human NCI-H460 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity in human NCI-H460 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31251621]
NCI-H460	IC₅₀	0.12 μM Compound: Epirubicin	Cytotoxicity against human NCI-H460 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 28119026]
NCI-H460	IC₅₀	6.74 mM Compound: Epirubicin	Cytotoxicity against human H460 cells after 72 hrs by MTT assay Cytotoxicity against human H460 cells after 72 hrs by MTT assay	[PMID: 22940450]
NIH3T3	IC₅₀	4.2 μM Compound: Epirubicin	Antiproliferative activity against mouse NIH/3T3 cells after 48 hrs by MTT assay Antiproliferative activity against mouse NIH/3T3 cells after 48 hrs by MTT assay	[PMID: 23287057]
OVCAR-3	IC₅₀	0.75 mM Compound: Epirubicin	Cytotoxicity against human OVCAR3 cells after 72 hrs by MTT assay Cytotoxicity against human OVCAR3 cells after 72 hrs by MTT assay	[PMID: 22940450]
PC-3	IC₅₀	0.16 μg/mL Compound: EPI	Cytotoxicity against human PC3 cells after 6 days by MTT method Cytotoxicity against human PC3 cells after 6 days by MTT method	[PMID: 21545109]
PC-3	IC₅₀	0.46 μM Compound: EPI	Cytotoxicity against human PC3 cells after 6 days by MTT assay Cytotoxicity against human PC3 cells after 6 days by MTT assay	[PMID: 22276679]
PC-3	IC₅₀	2.31 μM Compound: Epirubicin	Cytotoxicity against human PC-3 cells assessed as reduction in cell viability preincubated for 48 hrs and measured after 4 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as reduction in cell viability preincubated for 48 hrs and measured after 4 hrs by MTT assay	[PMID: 31761381]
PC-3	IC₅₀	5.7 μM Compound: EPI	Cytotoxicity in human PC3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity in human PC3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31251621]
PC-3	IC₅₀	5.7 μM Compound: Epirubicin	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 23287057]
SGC-7901	IC₅₀	0.51 mM Compound: Epirubicin	Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay	[PMID: 22940450]
SGC-7901	IC₅₀	5.16 μM Compound: Epirubicin	Anticancer activity against human SGC7901 cells after 72 hrs by MTT assay Anticancer activity against human SGC7901 cells after 72 hrs by MTT assay	[PMID: 29903662]
SK-OV-3	IC₅₀	0.498 μM Compound: Epirubicin	Cytotoxicity against human SK-OV-3 cells assessed as cell viability measured after 48 hrs by MTT assay Cytotoxicity against human SK-OV-3 cells assessed as cell viability measured after 48 hrs by MTT assay	[PMID: 38964974]
SNB-19	IC₅₀	2.3 μM Compound: EPI	Cytotoxicity in human SNB19 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity in human SNB19 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31251621]
T-24	IC₅₀	1.12 μM Compound: Epirubicin	Cytotoxicity against human T-24 cells expressing wild type p53 assessed as reduction in cell viability preincubated for 48 hrs and measured after 4 hrs by MTT assay Cytotoxicity against human T-24 cells expressing wild type p53 assessed as reduction in cell viability preincubated for 48 hrs and measured after 4 hrs by MTT assay	[PMID: 31761381]
T47D	IC₅₀	4.3 μM Compound: Epirubicin	Antiproliferative activity against human T47D cells after 48 hrs by MTT assay Antiproliferative activity against human T47D cells after 48 hrs by MTT assay	[PMID: 23287057]

In Vitro

Epirubicin (4'-Epidoxorubicin), like doxorubicin, exerts its antitumor effects by complex with DNA, resulting in damage to DNA and interference with the synthesis of DNA, RNA, and proteins. Epirubicin may also affect the integrity and activity of cellular membranes. Maximal cell kill caused by Epirubicin occurs during the S phase of the cell cycle. With higher concentrations effects are also seen in early G2 as well as G1 and M phases^[1].
Epirubicin display antineoplastic activity against most cancer cells. Epirubicin is cytotoxic to Hepatoma G2 cells with IC₅₀ of 1.6 μg/mL at 24 hr. 1.6 μg/mL Epirubicin induces apoptosis of Hep G2 cells, and higher activity of catalase by 50%, Se-dependent glutathione peroxidase by 110%, Cu, Zn-superoxide dismutase by 172% and Mn-superoxide dismutase by 135%. Epirbicin increases the cellular expression of NADPH-CYP 450 reductase, and reduces GST-π expression^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Epirubicin (4'-Epidoxorubicin) are clinically active against a broad range of tumor types, including breast cancer, malignant lymphomas, soft tissue sarcomas, lung cancer, pleural mesothelioma, gastrointestinal cancer, head and neck cancer, ovarian cancer, prostatic carcinoma, transitional bladder carcinoma and so on^[4].
Epirubicin at a dose of 3.5 mg/kg suppresses tumor mass of human breast tumor xenograft R-27 by 74.4 %^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 56420-45-2
Appearance Solid
Molecular Weight 543.52
Formula C₂₇H₂₉NO₁₁
Color Orange to red
SMILES

O=C(C1=C2C(O)=C3[C@@H](O[C@@]4([H])C[C@H](N)[C@@H](O)[C@H](C)O4)C[C@@](C(CO)=O)(O)CC3=C1O)C5=CC=CC(OC)=C5C2=O
Synonyms

4'-Epidoxorubicin
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Publications (38)

All Cell Proliferation/Viability AssayIn Vivo Efficacy StudyWB

Sort by:

Journal Impact Factor

Mol Cancer

Organoids derived from patients provide a new opportunity for research and individualized treatment of malignant peritoneal mesothelioma. [Abstract]

2024 Jan 10;23(1):12. PMID: 38200517
Cell Mol Immunol

Arsenic trioxide elicits prophylactic and therapeutic immune responses against solid tumors by inducing necroptosis and ferroptosis. [Abstract]

2023 Jan;20(1):51-64. PMID: 36447031

Epirubicin purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2023 Jan;20(1):51-64. [Abstract]

Comparison of drug (Epirubicin hydrochloride, EPI; Daunorubicin hydrochloride, DNR; Vinorelbine ditartrate, VNR; Oxaliplatin, OXA; Vincristine, VCR; Artemisinin, ART; Colchicine, COL) cytotoxicity to TC1 cells at the indicated doses and time points measured with CCK-8 assays. R.U. (Relative unit) was calculated from the average O.D. values in each condition as the indicator of cell viability (n = 3).
Adv Funct Mater

2026 Feb 1.
Mol Cell

Micropeptide PACMP inhibition elicits synthetic lethal effects by decreasing CtIP and poly(ADP-ribosyl)ation. [Abstract]

2022 Apr 7;82(7):1297-1312.e8. PMID: 35219381

Epirubicin purchased from MedChemExpress. Usage Cited in: Mol Cell. 2022 Apr 7;82(7):1297-1312.e8. [Abstract]

CCK8 assay to detect the survival of MCF7 cells transfected with indicated siRNAs and treated with 1 μM EPI (Epirubicin hydrochloride; for 24 h).

Epirubicin purchased from MedChemExpress. Usage Cited in: Mol Cell. 2022 Apr 7;82(7):1297-1312.e8. [Abstract]

CCK8 assay to detect the survival of MCF7 cells transfected with indicated siRNAs and treated with 1 μM EPI (Epirubicin hydrochloride; left) for 24 h or 0.5 μM EPI for 0-60 h (right).

Epirubicin purchased from MedChemExpress. Usage Cited in: Mol Cell. 2022 Apr 7;82(7):1297-1312.e8. [Abstract]

Indicated MCF7 cells were treated with 1 μM EPI (Epirubicin hydrochloride) for 24 h. The levels of γH2AX were analyzed by immunoblotting (IB). Numbers represent its relative intensities measured by ImageJ.

Epirubicin purchased from MedChemExpress. Usage Cited in: Mol Cell. 2022 Apr 7;82(7):1297-1312.e8. [Abstract]

Xenograft assay of lnc15.2-depleted and FL/FL∗-supplemented MDA-MB-231 cells (n = 5 per group). Tumor growth are shown. The arrow indicates each EPI (Epirubicin hydrochloride; 5 mg/Kg; i.p. on days 0, 4, 8 or 9) treatment.
Interdiscip Med

2025 Feb 24.
Cell Rep Med

CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]

2025 Apr 2:102053. PMID: 40187357
Cell Commun Signal

Targeting the MAGED2-TRIM28-FLNC axis overcomes chemoresistance in TNBC via EMT suppression. [Abstract]

2025 Nov 27;23(1):551. PMID: 41310667
Genome Med

Genomic and transcriptomic analysis of breast cancer identifies novel signatures associated with response to neoadjuvant chemotherapy. [Abstract]

2024 Jan 12;16(1):11. PMID: 38217005
Cell Death Discov

Epirubicin induces cardiotoxicity through disrupting ATP6V0A2-dependent lysosomal acidification and triggering ferroptosis in cardiomyocytes. [Abstract]

2024 Jul 24;10(1):337. PMID: 39048556
Br J Cancer

DRD4 promotes chemo-resistance and cancer stem cell-like phenotypes by mediating the activation of the Akt/β-catenin signaling axis in liver cancer. [Abstract]

2024 Oct;131(7):1212-1223. PMID: 39174739
Cancer Drug Resist

2026 Jun 8;9.
Cell Prolif

L-Se-methylselenocysteine sensitizes lung carcinoma to chemotherapy. [Abstract]

2021 May;54(5):e13038. PMID: 33793020
Anal Chem

Force-Dependent Intercalative Bulky DNA Adduct Formation Detected by Single-Molecule Stretching. [Abstract]

2022 Oct 4;94(39):13623-13630. PMID: 36129494
Cancer Cell Int

Organoids as a model system for researching human neuroendocrine tumor of the breast. [Abstract]

2024 Dec 27;24(1):433. PMID: 39731167
Food Funct

Combination of resveratrol and epirubicin to overcome chemoresistance in lung adenocarcinoma organoids: synergistic effects and translational implications. [Abstract]

2025 Aug 26;16(17):6786-6799. PMID: 40755405
Int J Pharm

Fucoidan based polymeric nanoparticles encapsulating epirubicin: A novel and effective chemotherapeutic formulation against colorectal cancer. [Abstract]

2024 Aug 26:664:124622. PMID: 39197799
J Biomed Inform

From Centralized to Ad-Hoc Knowledge Base Construction for Hypotheses Generation. [Abstract]

2023 Jun:142:104383. PMID: 37196989
ACS Appl Bio Mater

RA16-Modified DNA Tetrahedra: Targeted Delivery and Inhibition in Non-Small Cell Lung Cancer. [Abstract]

2025 Jun 16;8(6):4686-4698. PMID: 40366635
Int J Mol Sci

Metformin Alleviates Epirubicin-Induced Endothelial Impairment by Restoring Mitochondrial Homeostasis. [Abstract]

2022 Dec 25;24(1):343. PMID: 36613786
Microchem J

2025 Oct 15;218:115702.
Eur J Pharm Sci

Chemotherapy drug combinations induced maternal ovarian damage and long-term effect on fetal reproductive system in mice. [Abstract]

2024 Jul 21:106860. PMID: 39043317
J Mol Med (Berl)

Combination of PARP inhibitor and temozolomide to suppress chordoma progression. [Abstract]

2019 Aug;97(8):1183-1193. PMID: 31201471
Int J Cancer

Establishment of patient-derived organoids for guiding personalized therapies in breast cancer patients. [Abstract]

2024 Jul 15;155(2):324-338. PMID: 38533706
Mol Pharm

Superior Penetration and Cytotoxicity of HPMA Copolymer Conjugates of Pirarubicin in Tumor Cell Spheroid. [Abstract]

2019 Aug 5;16(8):3452-3459. PMID: 31294568
Cancer Res Treat

Establishment of Patient-Derived Organoids Using Ascitic or Pleural Fluid from Cancer Patients. [Abstract]

2023 Oct;55(4):1077-1086. PMID: 37309112
Breast Cancer

Quercetin Promote the Chemosensitivity in Organoids Derived from Patients with Breast Cancer. [Abstract]

2024 Dec 20:16:993-1004. PMID: 39720358
Genomics

The potential role of c-MYC and polyamine metabolism in multiple drug resistance in bladder cancer investigated by metabonomics. [Abstract]

2022 Jan;114(1):125-137. PMID: 34843906
Exp Cell Res

Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia. [Abstract]

2020 Aug 1;393(1):112054. PMID: 32376287
Yonsei Med J

miR-1301/TRIAP1 Axis Participates in Epirubicin-Mediated Anti-Proliferation and Pro-Apoptosis in Osteosarcoma. [Abstract]

2019 Sep;60(9):832-841. PMID: 31433581
Discov Oncol

Mucinous breast cancer organoids: an in vitro research model. [Abstract]

2025 May 19;16(1):814. PMID: 40388071
Asia Pac J Clin Oncol

Epirubicin may enhance the inhibition of hepatocellular carcinoma induced by iodine-125 seeds through downregulating WNT pathway. [Abstract]

2023 Jun;19(3):355-364. PMID: 36464954

Epirubicin purchased from MedChemExpress. Usage Cited in: Asia Pac J Clin Oncol. 2023 Jun;19(3):355-364. [Abstract]

The Epirubicin (EPI) + iodine-125 (¹²⁵I) group is significantly decreases the proliferation ability of HepG2 and SMMC7721 cells (cells are cultured for 2-3 weeks).

Epirubicin purchased from MedChemExpress. Usage Cited in: Asia Pac J Clin Oncol. 2023 Jun;19(3):355-364. [Abstract]

Epirubicin (EPI) promotes iodine-125 (¹²⁵I)-induced downregulation of the WNT pathway and enhances the radiosensitivity of HepG2 and SMMC7721 cells.
Turk J Biol

Combinatorial effect of epirubicin and 5-fluorouracil in the treatment of temozolomide-resistant glioblastoma cells. [Abstract]

2026 Mar 13;50(2):170-184. PMID: 42058124
Res Sq

2026 Jan 9.
Cell Biomater

2025 Jul 22.
bioRxiv

2023 Apr 17.
bioRxiv

2023 Jan 13.
Research Square Preprint

2021 Nov.
Research Square Preprint

2020 May.

Solvent & Solubility

In Vitro:

DMSO : 116.67 mg/mL (214.66 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.8399 mL

9.1993 mL

18.3986 mL

5 mM

0.3680 mL

1.8399 mL

3.6797 mL

10 mM

0.1840 mL

0.9199 mL

1.8399 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Protocol

Cell Assay^[3]

Hep G2 cells (500 cells/well, monolayer) are plated in a 96-well plate. The next day the cells are treated with Epirubicin in the medium. At the end of the incubation periods, 15% volume of MTT dye solution is added. After 1 hr of incubation at 37°C, an equal volume of solubilization/stop solution (dimethylsul-foxide) is added to each well for an additional 1 hr incubation. The absorbance of the reaction solution at 570 nm is recorded.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (284 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Cersosimo RJ, et al. Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol. 1986 Mar;4(3):425-39. [Content Brief]

[2]. Kashima H, et al. Epirubicin, Identified Using a Novel Luciferase Reporter Assay for Foxp3 Inhibitors, Inhibits Regulatory T Cell Activity. PLoS One. 2016 Jun 10;11(6):e0156643. [Content Brief]

[3]. Ozkan, A., et al. Epirubicin HCl toxicity in human-liver derived hepatoma G2 cells. Pol J Pharmacol, 2004. 56(4): p. 435-44. [Content Brief]

[4]. Bonadonna, G., et al. Drugs ten years later: epirubicin. Ann Oncol, 1993. 4(5): p. 359-69. [Content Brief]

[5]. Asanuma, F., et al. Antitumor activity of paclitaxel and epirubicin in human breast carcinoma, R-27. Folia Microbiol (Praha), 1998. 43(5): p. 473-4. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.8399 mL	9.1993 mL	18.3986 mL	45.9965 mL
	5 mM	0.3680 mL	1.8399 mL	3.6797 mL	9.1993 mL
	10 mM	0.1840 mL	0.9199 mL	1.8399 mL	4.5996 mL
	15 mM	0.1227 mL	0.6133 mL	1.2266 mL	3.0664 mL
	20 mM	0.0920 mL	0.4600 mL	0.9199 mL	2.2998 mL
	25 mM	0.0736 mL	0.3680 mL	0.7359 mL	1.8399 mL
	30 mM	0.0613 mL	0.3066 mL	0.6133 mL	1.5332 mL
	40 mM	0.0460 mL	0.2300 mL	0.4600 mL	1.1499 mL
	50 mM	0.0368 mL	0.1840 mL	0.3680 mL	0.9199 mL
	60 mM	0.0307 mL	0.1533 mL	0.3066 mL	0.7666 mL
	80 mM	0.0230 mL	0.1150 mL	0.2300 mL	0.5750 mL
	100 mM	0.0184 mL	0.0920 mL	0.1840 mL	0.4600 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Epirubicin

Anti-Infection Compound Library

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Metabolism/Protease Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Transcription Factor-Targeted Library

Rare Diseases Drug Library

Chemotherapy Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Off-patent Drug Library

Mitochondrial Toxicity Compound Library

Cell Death Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

RNA Binding Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Epirubicin

All DNA/RNA Synthesis Isoforms

All Topoisomerase Isoforms

All Antibiotic Isoforms

All FOXP Isoforms

Biological Activity

Chemical Information

Publications (38)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Epirubicin Related Classifications

HY-13624 Related Classifications